摘要
肝功能衰竭是由于多种因素引起的肝脏严重损害,其并发症多、病情进展快,预后极差。如何准确评估预后、指导临床制定合理的治疗方案是治疗的关键问题。目前应用较多的评估系统主要有:Child-Turotte-Pugh评分、终末期肝病模型、英国皇家医学院医院标准,急性生理、年龄和慢性健康评分和序贯器官衰竭评估等。近年来,一些反映肝功能衰竭预后的新兴生物标志物不断出现,显示了潜在的评估价值。本文对肝功能衰竭预后评估的研究进展作一综述。
Liver failure is serious liver damages characterized by many complications, rapid progression and poor prognosis. How to accurately predict the prognosis and guide treatment is the key problem. The assessment systems widely used include Child-Turotte-Pugh （CTP） score, model for end-stage liver disease （MELD）, King＇s College Hospital （KCH） criteria, acute physiology, age and chronic health evaluation （APACHE） and sequential organ failure assessment （SOFA）. Recently, a variety of emerging biomarkers showed potential values for prognosis assessment. This paper reviews on current progresses of prognosis assessment in liver failure.
出处
《中华实验和临床感染病杂志（电子版）》
CAS
2015年第5期41-44,共4页
Chinese Journal of Experimental and Clinical Infectious Diseases(Electronic Edition)
基金
"十二五"国家科技重大专项(No.2012ZX10005-005)
四川省中医药管理局科研课题(No.2012-A-092)
关键词
肝功能衰竭
预后
评估
Liver failure
Prognosis
Assessment
